NKTR vs. URGN

Last updated Jun 3, 2026

NKTR (Nektar Therapeutics) and URGN (UroGen Pharma Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, NKTR returned -26.23%/yr vs 7.68%/yr for URGN. At a 0.25 correlation, their price movements are largely independent.

Performance

NKTR vs. URGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nektar Therapeutics (NKTR) and UroGen Pharma Ltd. (URGN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NKTR achieves a 38.51% return, which is significantly higher than URGN's 13.32% return.

NKTR

• 1D: -8.30%
• 1M: -32.27%
• YTD: 38.51%
• 6M: 6.76%
• 1Y: 390.21%
• 3Y*: 84.73%
• 5Y*: -26.23%
• 10Y*: -13.07%

URGN

• 1D: -1.81%
• 1M: 15.39%
• YTD: 13.32%
• 6M: 8.86%
• 1Y: 448.35%
• 3Y*: 39.67%
• 5Y*: 7.68%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

NKTR vs. URGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NKTR Nektar Therapeutics	38.51%	203.08%	64.60%	-75.00%	-83.27%	-20.53%	-21.26%	-34.32%	-44.96%	221.42%
URGN UroGen Pharma Ltd.	13.32%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%

Correlation

The correlation between NKTR and URGN is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.13
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.23
Correlation (All Time) Calculated using the full available price history since May 5, 2017	0.25

The correlation between NKTR and URGN shifts across timeframes, from 0.13 (1 year) to 0.25 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap NKTR : $1.45B URGN : $1.33B
EPS NKTR : -$8.64 URGN : -$2.73
PS Ratio NKTR : 19.26 URGN : 9.22
Total Revenue (TTM) NKTR : $55.63M URGN : $140.49M
Gross Profit (TTM) NKTR : $44.58M URGN : $126.24M
EBITDA (TTM) NKTR : -$121.05M URGN : -$117.04M

Return for Risk

NKTR vs. URGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NKTR

NKTR Risk / Return Rank: 95
NKTR Sharpe Ratio Rank: 88
NKTR Sortino Ratio Rank: 98
NKTR Omega Ratio Rank: 95
NKTR Calmar Ratio Rank: 97
NKTR Martin Ratio Rank: 96

URGN

URGN Risk / Return Rank: 97
URGN Sharpe Ratio Rank: 98
URGN Sortino Ratio Rank: 98
URGN Omega Ratio Rank: 95
URGN Calmar Ratio Rank: 98
URGN Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NKTR vs. URGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NKTR	URGN	Difference
Sharpe ratio Return per unit of total volatility	2.12	4.62	-2.50
Sortino ratio Return per unit of downside risk	5.22	5.13	+0.09
Omega ratio Gain probability vs. loss probability	1.59	1.60	-0.01
Calmar ratio Return relative to maximum drawdown	9.43	12.46	-3.03
Martin ratio Return relative to average drawdown	21.73	25.96	-4.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NKTR vs. URGN - Sharpe Ratio Comparison

The current NKTR Sharpe Ratio is 2.12, which is lower than the URGN Sharpe Ratio of 4.62. The chart below compares the historical Sharpe Ratios of NKTR and URGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	NKTR	URGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.12	4.62	-2.50
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.22	0.08	-0.30
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.13	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.00	0.09	-0.09

Drawdowns

NKTR vs. URGN - Drawdown Comparison

The maximum NKTR drawdown since its inception was -99.61%, which is greater than URGN's maximum drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for NKTR and URGN.

Drawdown Indicators

	NKTR	URGN	Difference
Max Drawdown Largest peak-to-trough decline	-99.61%	-93.98%	-5.63%
Max Drawdown (1Y) Largest decline over 1 year	-46.54%	-42.22%	-4.32%
Max Drawdown (3Y) Largest decline over 3 years	-73.20%	-82.64%	+9.44%
Max Drawdown (5Y) Largest decline over 5 years	-97.76%	-82.64%	-15.12%
Max Drawdown (10Y) Largest decline over 10 years	-99.61%	—	—
Current Drawdown Current decline from peak	-96.40%	-59.38%	-37.02%
Average Drawdown Average peak-to-trough decline	-68.31%	-61.55%	-6.76%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.20%	20.26%	-0.06%

Volatility

NKTR vs. URGN - Volatility Comparison

The current volatility for Nektar Therapeutics (NKTR) is 10.93%, while UroGen Pharma Ltd. (URGN) has a volatility of 20.26%. This indicates that NKTR experiences smaller price fluctuations and is considered to be less risky than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NKTR	URGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.93%	20.26%	-9.33%
Volatility (6M) Calculated over the trailing 6-month period	64.10%	46.54%	+17.56%
Volatility (1Y) Calculated over the trailing 1-year period	185.99%	98.75%	+87.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	121.81%	91.53%	+30.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	97.16%	79.57%	+17.59%

Dividends

NKTR vs. URGN - Dividend Comparison

Neither NKTR nor URGN has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NKTR and URGN in my portfolio?

NKTR and URGN have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NKTR or URGN?

URGN has higher volatility (20.26%) compared to NKTR (10.93%). In terms of maximum drawdown, NKTR dropped -99.61% vs URGN's -93.98%.

Which has better risk-adjusted returns?

URGN currently has the higher Sharpe Ratio (4.62 vs 2.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.